Method and system for drug utilization review

• US 20040010511A1
• Filed: 07/11/2002
• Published: 01/15/2004
• Est. Priority Date: 07/11/2002
• Status: Abandoned Application

• Current Assignee: Victor V. Gogolak
• Original Assignee: Victor V. Gogolak
• Inventors: Gogolak, Victor V.
• Application Number:
  US10/192,659
• Publication Number:
  US 20040010511A1
• Time in Patent Office: Days
• US Class Current: 707/104.1
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

Conducting drug utilization review. The method comprising: collecting patient data, drug data, and practice data, normalizing the terminology of each data, and determining, from among the drugs identified by the drug data, each drug that addresses a patient'"'"'s characteristics as defined in the patient data, and that meets the requirements of the practice data. The drug data contains information regarding at least the risk of adverse reaction to each drug, and rules for prescribing each drug.

Claims

1. A method for conducting drug utilization review, the method comprising:

collecting patient data, drug data, and practice data,

the drug data containing;

information regarding at least the risk of adverse reaction to each drug, and

rules for prescribing each drug;

normalizing the terminology of each data; and

determining, from among the drugs identified by the drug data, each drug that addresses a patient'"'"'s characteristics as defined in the patient data, and that meets the requirements of the practice data.

2. The method of claim 1 wherein determined drugs are presented in order of risk of adverse reaction.

3. The method of claim 1 wherein determining, from among the drugs identified by the drug data, each drug that addresses a patient'"'"'s characteristics as defined in the patient data, and that meets the requirements of the practice data comprises:

identifying to a user, at least one element of data missing from the determination analysis.

4. The method of claim 3 wherein determined drugs are presented in order of risk of adverse reaction.

5. A method for conducting drug utilization review, the method comprising:

collecting patient data, drug data, and practice data,

the drug data containing;

information regarding at least the risk of adverse reaction to each drug, and

rules for prescribing each drug;

normalizing the terminology of each data; and

determining, for at one subject drug among the drugs identified in the drug data and considering the practice data, an estimate of the appropriateness of each subject drug for the subject patient.

6. The method of claim 5 wherein determining, for at one subject drug among the drugs identified in the drug data and considering the practice data, an estimate of the appropriateness of each subject drug for the subject patient comprises:

identifying to a user, at least one element of data missing from the determination analysis.